SciSparc Secures Strategic Advantage with Grant of European Patent

This grant not only reinforces SciSparc's position in a key market, but also enhances its competitive edge in the global pharmaceutical landscape. TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the European Patent Office granted the Company's patent application titled "Co ...